Sangamo Therapeutics. has filed a patent for methods and compositions to inactivate TCR and/or HLA genes using engineered nucleases. The patent includes polynucleotides encoding nucleases, vectors, and cells comprising nucleases. The claim specifically mentions a polynucleotide encoding a zinc finger nuclease with certain designated components. GlobalData’s report on Sangamo Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Sangamo Therapeutics, Zinc-finger nucleases was a key innovation area identified from patents. Sangamo Therapeutics's grant share as of September 2023 was 46%. Grant share is based on the ratio of number of grants to total number of patents.
The patent is filed for a polynucleotide encoding a zinc finger nuclease
A recently filed patent (Publication Number: US20230295563A1) describes various claims related to polynucleotides encoding zinc finger nucleases (ZFNs) and their applications in modifying specific genes in cells. The patent claims cover the use of specific ZFNs, engineered FokI cleavage domains, and linkers between the cleavage domain and the ZFP.
The first claim (Claim 1) describes a polynucleotide encoding a zinc finger nuclease, which includes a ZFP from one of the designated ZFNs (68957, 72678, 72732, or 72748), an engineered FokI cleavage domain, and a linker between the cleavage domain and the ZFP. Claim 2 specifies that the polynucleotide may also include a 2A sequence.
Claim 3 covers a pharmaceutical composition comprising the polynucleotide described in Claim 1. This suggests that the polynucleotide may have potential therapeutic applications.
Claim 4 describes a method of modifying an endogenous beta-2-microglobulin (B2M) gene in a cell by administering the polynucleotide from Claim 1. Claim 5 adds the step of introducing an exogenous sequence into the cell, which is inserted into the endogenous B2M gene.
Claim 6 specifies that the modification of the endogenous B2M gene in Claim 4 may involve a deletion.
Claim 7 outlines a method of producing a genetically modified cell with a genomic modification within an endogenous B2M gene. This involves contacting a cell with the polynucleotide from Claim 1, subjecting the cell to conditions conducive to expressing the fusion protein, and modifying the endogenous B2M gene with the expressed fusion protein.
Claim 8 covers a kit comprising the polynucleotide described in Claim 1, indicating that the patent also includes provisions for commercial applications.
The patent also includes similar claims (Claims 9-17) for a different set of ZFNs and their applications in modifying an endogenous T cell receptor (TCR) gene in a cell.
Overall, this patent describes specific polynucleotides encoding zinc finger nucleases and their applications in modifying specific genes in cells. The claims cover various aspects of the invention, including the composition of the polynucleotides, methods of gene modification, and kits for commercial use.
To know more about GlobalData’s detailed insights on Sangamo Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
